|Drug Name:||Buprenorphine Hydrochloride|
Buprenorphine HCl is supplied in sealed vials and poses no known environmental risk to health care providers.
Accidental dermal exposure should be treated by removal of any contaminated clothing and rinsing the affected area with water.Buprenorphine HCl is a potent narcotic, and like all drugs of this class has been associated with abuse and dependence among health care providers.To control the risk of diversion, it is recommended that measures appropriate to the health care setting be taken to provide rigid accounting, control of wastage, and restriction of access.Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
As with other potent opioids, clinically significant respiratory depression may occur within the recommended dose range in patients receiving therapeutic doses of buprenorphine.
Buprenorphine HCl should be used with caution in patients with compromised respiratory function (e.g., chronic obstructive pulmonary disease, cor pulmonale, decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression).
Particular caution is advised if buprenorphine HCl is administered to patients taking or recently receiving drugs with CNS/respiratory depressant effects.
In patients with the physical and/or pharmacological risk factors above, the dose should be reduced by approximately one-half.NALOXONE MAY NOT BE EFFECTIVE IN REVERSING THE RESPIRATORY DEPRESSION PRODUCED BY BUPRENORPHINE HCl.THEREFORE, AS WITH OTHER POTENT OPIOIDS, THE PRIMARY MANAGEMENT OF OVERDOSE SHOULD BE THE REESTABLISHMENT OF ADEQUATE VENTILATION WITH MECHANICAL ASSISTANCE OF RESPIRATION, IF REQUIRED.